ConductScience.org, home

Library / Trials

Glucose Variability and Cognition in Prediabetes

NCT04201600, Completed, University of Maryland, Baltimore

Trial 9

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleGlucose Variability and Cognition in PrediabetesClinicalTrials.gov
NCT numberNCT04201600ClinicalTrials.gov
StatusCompletedClinicalTrials.gov
Enrollment66 participants, actualClinicalTrials.gov
Lead sponsorUniversity of Maryland, BaltimoreClinicalTrials.gov
ConditionsGlucose Metabolism Disorders (Including Diabetes Mellitus), Cognitive Decline, PreDiabetes, Aging, Alzheimer's DiseaseClinicalTrials.gov
InterventionsContinuous Glucose Monitoring System (CGMS)ClinicalTrials.gov
First posted2019-12-17ClinicalTrials.gov
Last updated2026-10-15ClinicalTrials.gov

Registered outcomes 4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryAggregate Executive Functioning ScoreDay 1
Scores on the following standard neurocognitive tests will be z-transformed based on their respective means and standard deviations and combined into one aggregate total score such that higher values mean better executive functioning: Trails Making A and B, The Stroop-Color Word Test, Digit Span subscale of the Wechsler Adult Intelligence Scale - Revised (WAIS-IV), Digit Symbol Substitution Test (DSST)
ClinicalTrials.gov
PrimaryAggregate Memory ScoreDay 1
Scores on the following standard neurocognitive tests will be z-transformed based on their respective means and standard deviations and combined into one aggregate total score such that higher values mean better memory ability: California Verbal Learning Test, Benton Visual Retention Test
ClinicalTrials.gov
OtherLevel of Plasma phosphorylated tau 181 (p-tau181)Single assessment between Day 10-14Plasma-based AD biomarkers of tau phosphorylation assayed in duplicate by Simoa immunoassay on the HD-X platformClinicalTrials.gov
OtherLevel of Plasma amyloid beta 42/40 ratio (Aβ42/Aβ40)Single assessment between Day 10-14Ratio of plasma amyloid beta 42 to amyloid beta 40, assayed in duplicate by Simoa immunoassay on the HD-X platformClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource
R21AG077647Glucose Variability as a Digital Biomarker for Preclinical AD Risk in Prediabetes.KHAMBATY, TASNEEMUNIVERSITY OF MARYLAND BALTIMORE COUNTYNATIONAL INSTITUTE ON AGING2023 to 2024NIH RePORTER

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 4

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource
Digit Span TestPrimary outcomeConductCognition
Stroop Color-Word TestPrimary outcomeConductCognition
Symbol CodingPrimary outcomeConductCognition
Verbal LearningPrimary outcomeConductCognition

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)